Skip to main content

Table 4 Clinical characteristics of the 19 Mycobacterium avium complex lung disease patients with chronic Pseudomonas aeruginosa infection

From: Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease

No. Age Sex BMI CCI Underlyingdisease MACLD duration years Hb CRP %FVC %FEV1 Sputumsmear/ culturea Cavity Modified Reiff score Treatment status for MACLD Treatment regimenb Treatment duration, years
1 74 F 17.3 0   10.3 13.1 1.1 99 86 - / - + 7 Current CAM + RFP 8.8
2 76 F 16.2 1 Old pTB, GERD 2.3 12.1 0.0 95 86 - / + 3 Never   
3 75 M 20.2 1 LC post-lobectomy 3.2 13.8 0.5 71 55 + / + 4 Current CAM + EB + RFP 3.4
4 76 F 17.3 1 MCTD 2.1 11.0 0.2 94 114 - / + 5 Never   
5 57 F 18.8 1 RA 5.3 11.7 4.2 68 54 - / - 4 Current CAM + EB + RFP 5.2
6 69 F 26.1 0   15.9 13.1 0.3 78 68 - / - + 7 Previous CAM + RFP + EB + KM 4.3
7 77 M 21.4 1 Old pTB, ABPM 6.5 9.8 0.2 116 105 - / - 3 Never   
8 77 F 14.9 1   1.9 12.2 0.0 98 102 + / + 7 Never   
9 67 M 18.5 0 Old pTB 2.3 14.6 0.1 112 83 - / - 1 Current CAM + EB + RFP 2.3
10 74 F 19.5 0   13.0 13.5 1.2 87 75 - / - 10 Current CAM + EB + RFP 11.4
11 81 F 18.4 0   14.8 11.0 0.3 103 102 + / + 7 Never   
12 67 F 21.2 1 RA 3.3 13.0 2.4 98 71 - / - 6 Never   
13 73 F 18.5 0   9.7 10.5 5.4 80 82 - / - + 11 Never   
14 71 M 21.9 2 Liver cirrhosis 5.1 15.0 0.1 102 82 - / + 6 Never   
15 69 M 16.9 0 Old pTB 6.5 12.7 1.9 58 65 - / + + 8 Current CAM + EB + RFP 1.7
16 77 F 20.9 1   9.5 12.0 5.0 92 70 - / - 2 Never   
17 63 F 16.8 1   4.3 11.7 0.2 69 64 - / + 5 Current CAM + RFP 4.1
18 74 F 21.4 1   0.6 13.4 0.0 106 98 - / + 2 Never   
19 35 F 18.9 0 Chronic sinusitis 14.5 10.7 0.0 75 66 - / - 5 Current AZM + RFP + EB 13.4
  1. BMI, body mass index; CCI, Charlson comorbidity index; MACLD, Mycobacterium avium complex lung disease; Hb, haemoglobin; CRP, C-reactive protein; FVC, forced vital capacity; FEV 1, forced expiratory volume in the first second; CAM, clarithromycin; RFP, rifampicin; pTB, pulmonary tuberculosis; GERD, gastroesophageal reflux disease; LC, lung cancer; EB, ethambutol; MCTD, mixed connective tissue disease; RA, rheumatoid arthritis; KM, kanamycin; ABPM, allergic bronchopulmonary mycosis; AZM, azithromycin;
  2. aSputum smear or culture for mycobacterium. bTreatment regimen included multiple antimicrobial therapy for MACLD